Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Expected to rise, 2034 | ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Bioscien

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market growth is driven by factors like increase in the prevalence of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market report [https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market size, share, Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market size growth forward.

Some of the key highlights from the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Insights Report:

*
Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) treatment outlook.

*
In July 2024, Phathom Pharmaceuticals obtained an expanded indication for its acid suppression medication. The FDA approved the inclusion of heartburn relief associated with non-erosive Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) in Voquezna's label.

*
In November 2023, the FDA approved VOQUEZNA (vonoprazan) tablets in 10 mg and 20 mg dosages, a pioneering potassium-competitive acid blocker (PCAB), as a new treatment option for adults. This medication is indicated for healing all grades of Erosive Esophagitis, also known as Erosive GERD, as well as for maintaining healing and relieving heartburn associated with Erosive GERD.

*
In May 2023, Phathom Pharmaceuticals resubmitted its New Drug Application to the FDA for vonoprazan, seeking approval for the treatment of erosive Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) (GERD), also known as erosive esophagitis.

*
In June 2022, Zydus Lifesciences received FDA approval to market Famotidine tablets in 20mg and 40mg strengths. Famotidine, a histamine H2 receptor blocker, works by reducing stomach acid and is used to relieve and prevent heartburn and other symptoms of acid reflux.

*
Several pharmaceutical companies, including Cinclus Pharma, Braintree (part of Sebela Pharmaceuticals), and N-Zyme Biomedical Inc., are actively researching and developing new therapies to meet the unmet needs of GERD patients.

*
As per DelveInsight analysis, the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Landscape [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Overview

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) (GERD) is a chronic condition in which stomach contents, including acid and bile, flow back into the esophagus, causing symptoms like heartburn, regurgitation, and chest pain. It commonly results from a dysfunction of the lower esophageal sphincter (LES), which typically prevents gastric contents from entering the esophagus. Contributing factors include hiatal hernia, poor esophageal motility, obesity, and certain dietary habits, such as consuming spicy or fatty foods, caffeine, and alcohol. GERD can present as non-erosive reflux disease (NERD), where no visible damage occurs to the esophageal lining, or as erosive esophagitis, which involves inflammation and damage to the esophageal tissue.

Symptoms of GERD can vary in intensity and may include heartburn (a burning sensation in the chest, often aggravated by eating or lying down), regurgitation of acid into the mouth, difficulty swallowing (dysphagia), chest pain, and chronic cough. These symptoms can negatively affect quality of life and may lead to complications such as esophageal strictures, Barrett's esophagus, and esophageal adenocarcinoma if not treated.

Do you know the treatment paradigms for different countries? Download our Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Sample Report [https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology Insights

*
Our analysis shows that the prevalence of GERD in North America ranges from 18% to 28%, while in Europe, it varies from 9% to 26%, indicating a considerable disease burden across both regions.

*
We also found that females have a higher prevalence of GERD compared to males, suggesting a gender disparity in the occurrence of the condition. This highlights the importance of addressing gender-specific factors in GERD management and treatment. The higher prevalence in females may be due to factors such as hormonal changes, differences in esophageal motility, and anatomical differences.

*
Additionally, our findings indicate that the age group of 50-59 years has the highest prevalence of GERD, while those aged 70 and above have the lowest. This trend could be linked to age-related changes in gastrointestinal function, lifestyle factors, and the presence of comorbidities in older individuals.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology Segmentation

DelveInsight's Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) historical patient pools and forecasted Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Prevalence

*
Age-Specific Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Prevalence

*
Gender-Specific Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Prevalence

*
Diagnosed and Treatable Cases of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

Visit for more @ Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiological Insights [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Insights:

*
Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.

*
According to DelveInsight's patient-based forecasting model, the total aHUS market size in the 7MM was approximately USD 1,300 million in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.

*
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.

*
Among emerging therapies for aHUS, Novartis' iptacopan and Roche's crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Outlook

The management of GERD is divided into five stages: four stages of medical management and one stage involving surgical intervention. The goal of treatment is to reduce esophageal exposure to reflux, alleviate symptoms, heal the esophagus, prevent complications, and maintain remission. Most GERD patients can manage symptoms and promote healing through lifestyle changes and drug therapy without requiring surgery. Surgery is considered for those with severe symptoms, erosive esophagitis, or disease complications despite adequate medication.

Lifestyle changes, such as elevating the head of the bed, reducing fat intake, quitting smoking, limiting alcohol, losing weight, and avoiding large meals and certain foods, are essential throughout treatment.

For mild symptoms, periodic drug therapy is often necessary, using antacids, alginic acid, or over-the-counter H2-receptor blockers. Antacids offer quick symptom relief by neutralizing gastric acid but are not used alone for esophageal healing due to their high dosage requirements. Alginic acid forms a mechanical barrier over the refluxate, protecting the esophagus. H2-receptor blockers provide longer relief, making them more suitable for symptom prevention.

For moderate to severe symptoms, scheduled pharmacologic therapy is required. Proton pump inhibitors (PPIs), such as Dexilant (dexlansoprazole), are used to suppress gastric acid, heal esophagitis, and maintain remission.

Surgery may be needed if medical therapy fails or complications arise, such as large hiatal hernia, Barrett's esophagus, severe esophagitis, recurrent strictures, or significant pulmonary symptoms. Noncompliance, financial barriers, and relapse of symptoms can also contribute to the need for surgery.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Marketed Drugs

*
VOQUEZNA (vonoprazan): Phathom Pharmaceuticals, Inc.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Emerging Drugs

*
BLI5100 (Tegoprazan): Braintree/ Sebela Pharmaceuticals

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Key Companies

*
ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others

For more information, visit Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) epidemiology in the 7MM

*
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) marketed and emerging therapies

*
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) companies

*
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market drivers and barriers

Table of Contents:

1 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Key Comprehensive Insights

2 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Report Introduction

3 Competitive Intelligence Analysis for Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

4 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Analysis Overview at a Glance

5 Executive Summary of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

6 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology and Market Methodology

7 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology and Patient Population

8 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Patient Journey

9 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Treatment Algorithm, Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Current Treatment, and Medical Practices

10 Key Endpoints in Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Clinical Trials

11 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Marketed Therapies

12 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Emerging Therapies

13 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD): 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

16 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Key Opinion Leaders Reviews

18 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Drivers

19 Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Epidemiology 2034

DelveInsight's "Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Pipeline 2024

"Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market. A detailed picture of the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) pipeline landscape is provided, which includes the disease overview and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-hypertension-associated-with-interstitial-lung-disease-phild-market-expected-to-rise-2034-ddpharma-arog-pharmaceuticals-chong-kun-dang-pharmaceutical-cinclus-pharma-cogent-bioscien]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer:Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.